Global Rivaroxaban Market Growth at a CAGR of 8.2% during 2018-2025

Posted on 2018-06-19 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, June 19, 2018: A newly compiled business intelligent report, titled “Global Rivaroxaban Market” Research Report 2018 has been publicized to the vast archive of Market Research Hub (MRH) online repository. The study revolves around the analysis of Rivaroxaban Market, covering key industry developments and market opportunity map during the mentioned forecast period. This report further conveys quantitative & qualitative analysis on the concerned market, providing a 360 view on current and future market prospects. As the report proceeds, information regarding the prominent trends as well as opportunities in the key geographical segments have also been explained, thus enabling companies to be able to make region-specific strategies for gaining competitive lead.

Click here for Free Sample Report@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=1831556

This report studies the global Rivaroxaban market status and forecast, categorizes the global Rivaroxaban market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa.

Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutical. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 812 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global average price of Rivaroxaban is in the decreasing trend, from 5.62 USD/Unit in 2011 to 5.34 USD/Unit in 2015. With the situation of global economy, prices will be in slowly decreasing trend in the following five years.
Bayer is the only supplier of Rivaroxaban enjoying production market share100% in 2015 and it will still in this situation until 2023.
The global Rivaroxaban market is valued at 5860 million US$ in 2017 and will reach 11000 million US$ by the end of 2025, growing at a CAGR of 8.2% during 2018-2025.

The major manufacturers covered in this report
Bayer
J&J

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
North America
Europe
China
Japan
Southeast Asia
India

We can also provide the customized separate regional or country-level reports, for the following regions:
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Rest of Asia-Pacific
Europe
Germany
France
UK
Italy
Spain
Russia
Rest of Europe
Central & South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Saudi Arabia
Turkey
Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
2.5 mg
10 mg
15 mg
20 mg
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)

Browse Full Report with TOC@ https://www.marketresearchhub.com/report/global-rivaroxaban-market-research-report-2018-report.html

Table of Contents

Global Rivaroxaban Market Research Report 2018
1 Rivaroxaban Market Overview
1.1 Product Overview and Scope of Rivaroxaban
1.2 Rivaroxaban Segment by Type (Product Category)
1.2.1 Global Rivaroxaban Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)
1.2.2 Global Rivaroxaban Production Market Share by Type (Product Category) in 2017
1.2.3 2.5 mg
1.2.4 10 mg
1.2.5 15 mg
1.2.6 20 mg
1.3 Global Rivaroxaban Segment by Application
1.3.1 Rivaroxaban Consumption (Sales) Comparison by Application (2013-2025)
1.3.2 Acute Coronary Syndrome (ACS)
1.3.3 Venous Thromboembolism (VTE)
1.4 Global Rivaroxaban Market by Region (2013-2025)
1.4.1 Global Rivaroxaban Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)
1.4.2 North America Status and Prospect (2013-2025)
1.4.3 Europe Status and Prospect (2013-2025)
1.4.4 China Status and Prospect (2013-2025)
1.4.5 Japan Status and Prospect (2013-2025)
1.4.6 Southeast Asia Status and Prospect (2013-2025)
1.4.7 India Status and Prospect (2013-2025)
1.5 Global Market Size (Value) of Rivaroxaban (2013-2025)
1.5.1 Global Rivaroxaban Revenue Status and Outlook (2013-2025)
1.5.2 Global Rivaroxaban Capacity, Production Status and Outlook (2013-2025)

2 Global Rivaroxaban Market Competition by Manufacturers
2.1 Global Rivaroxaban Capacity, Production and Share by Manufacturers (2013-2018)
2.1.1 Global Rivaroxaban Capacity and Share by Manufacturers (2013-2018)
2.1.2 Global Rivaroxaban Production and Share by Manufacturers (2013-2018)
2.2 Global Rivaroxaban Revenue and Share by Manufacturers (2013-2018)
2.3 Global Rivaroxaban Average Price by Manufacturers (2013-2018)
2.4 Manufacturers Rivaroxaban Manufacturing Base Distribution, Sales Area and Product Type
2.5 Rivaroxaban Market Competitive Situation and Trends
2.5.1 Rivaroxaban Market Concentration Rate
2.5.2 Rivaroxaban Market Share of Top 3 and Top 5 Manufacturers
2.5.3 Mergers & Acquisitions, Expansion

3 Global Rivaroxaban Capacity, Production, Revenue (Value) by Region (2013-2018)
3.1 Global Rivaroxaban Capacity and Market Share by Region (2013-2018)
3.2 Global Rivaroxaban Production and Market Share by Region (2013-2018)
3.3 Global Rivaroxaban Revenue (Value) and Market Share by Region (2013-2018)
3.4 Global Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.5 North America Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.6 Europe Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.7 China Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.8 Japan Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.9 Southeast Asia Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)
3.10 India Rivaroxaban Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

Continued… @@

Enquire about this Report@ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1831556

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceutical market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick